Mutational heterogeneity in cancer and the search for new cancer-associated genes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Major international projects are underway that are aimed at creating a comprehensive catalogue of all the genes responsible for the initiation and progression of cancer. These studies involve the sequencing of matched tumour-normal samples followed by mathematical analysis to identify those genes in which mutations occur more frequently than expected by random chance. Here we describe a fundamental problem with cancer genome studies: as the sample size increases, the list of putatively significant genes produced by current analytical methods burgeons into the hundreds. The list includes many implausible genes (such as those encoding olfactory receptors and the muscle protein titin), suggesting extensive false-positive findings that overshadow true driver events. We show that this problem stems largely from mutational heterogeneity and provide a novel analytical methodology, MutSigCV, for resolving the problem. We apply MutSigCV to exome sequences from 3,083 tumour-normal pairs and discover extraordinary variation in mutation frequency and spectrum within cancer types, which sheds light on mutational processes and disease aetiology, and in mutation frequency across the genome, which is strongly correlated with DNA replication timing and also with transcriptional activity. By incorporating mutational heterogeneity into the analyses, MutSigCV is able to eliminate most of the apparent artefactual findings and enable the identification of genes truly associated with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reproducibility of scientific findings has been called into question.”
From Evaluating replicability of laboratory experiments in economics (2016) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Melanoma has one of the highest rates of mutation of any cancer16.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [16]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cancer cells are genetically unstable, which contributes to their uncontrolled proliferation and the expression of antigens that can be recognized by the immune system.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 2×
“…(GBM) 2 and lung adenocarcinoma 1,4 ; CSMD3 in ovarian cancer 2 ; PCLO in diffuse large B-cell lymphoma (DLBCL) 9 ; MUC16 in lung squamous carcinoma 11 , breast cancer 12 and DLBCL 8 ; MUC4 in melanoma 13 ; olfactory receptor OR2L13 in GBM 14 ; and TTN in breast cancer 12 and other tumor types 15 .”
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationPatterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“…genes have already cropped up in recently published cancer genome studies, for example: LRP1B in glioblastoma (GBM) 2 and lung adenocarcinoma 1,4 ; CSMD3 in ovarian cancer 2 ; PCLO in diffuse large B-cell lymphoma (DLBCL) 9 ; MUC16 in lung squamous carcinoma 11 , breast cancer 12 and DLBCL 8…”
Self-citationThe Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,504 · cited 2×
“Recent studies have also implicated HPV in head-and-neck cancers 5 .”
InfluentialSelf-citationMutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909 · cited 3×
“Recent work 19,20 has shown that the TpC mutations tend to occur in proximity to one another, consistent with the activity of APOBEC enzymes in damaged long single-strand DNA regions.”
Influential
Cited by
Items 701–800 of 1,039
Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise
Kim, J., Akbani, R., Creighton, C. J., Lerner, S. P., Weinstein, J. N., Getz, G. A., & Kwiatkowski, D. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1215 · Cited by 147
Self-citationImmune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells
Tucci, M., Passarelli, A. M., Mannavola, F., Felici, C., Stucci, L. S., Cives, M., & Silvestris, F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01148 · Cited by 154
Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia
Seki, M., Kimura, S., Isobe, T., Yoshida, K., Ueno, H., Nakajima-Takagi, Y., Wang, C., Lin, L., Kon, A., Suzuki, H., et al. (2017) · Nature Genetics · doi:10.1038/ng.3900 · Cited by 138
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 150
Self-citationEXPANDS: expanding ploidy and allele frequency on nested subpopulations
Andor, N., Harness, J. V., Müller, S., Mewes, H. W., & Petritsch, C. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt622 · Cited by 137
Colli, L. M., Machiela, M. J., Myers, T. A., Jessop, L., Yu, K., & Chanock, S. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0170 · Cited by 137
Layer, J. P., Kronmüller, M., Quast, T., Konijnenberg, D., Effern, M., Hinze, D., Althoff, K., Schramm, A. R., Westermann, F., Peifer, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320626 · Cited by 147
Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy
Gai, W., & Sun, K. (2019) · Genes · doi:10.3390/genes10010032 · Cited by 143
DNA methylation in thyroid cancer
Zafón, C., Gil, J., Pérez-González, B., & Jordà, M. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0093 · Cited by 153
Competitive glucose metabolism as a target to boost bladder cancer immunotherapy
Afonso, J., Santos, L. L., Longatto‐Filho, A., & Baltazar, F. (2020) · Nature Reviews Urology · doi:10.1038/s41585-019-0263-6 · Cited by 144
Mutational signature distribution varies with DNA replication timing and strand asymmetry
Tomkova, M., Tomek, J., Kriaucionis, S., & Schuster-Böckler, B. (2018) · Genome Biology · doi:10.1186/s13059-018-1509-y · Cited by 137
Gossage, L., Murtaza, M., Slatter, A. F., Lichtenstein, C. P., Warren, A. Y., Haynes, B., Marass, F., Roberts, I., Shanahan, S. J., Claas, A., et al. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22116 · Cited by 145
Notch Activation as a Driver of Osteogenic Sarcoma
Tao, J., Jiang, M.-M., Jiang, L., Salvo, J. S., Zeng, H.-C., Dawson, B., Bertin, T. K., Rao, P. H., Chen, R., Donehower, L. A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.023 · Cited by 134
“Gainof-function mutations in NOTCH1 have been found in approximately 10% of cases of non-small-cell lung cancer (Lawrence et al., 2013; Westhoff et al., 2009), the leading cause of cancer-related deaths.”
BackgroundComprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
Madan, V., Shyamsunder, P., Han, L., Mayakonda, A., Nagata, Y., Sundaresan, J., Kanojia, D., Yoshida, K., Ganesan, S., Hattori, N., et al. (2016) · Leukemia · doi:10.1038/leu.2016.69 · Cited by 143
Zhang, J., Späth, S. S., Marjani, S. L., Zhang, W., & Pan, X. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby007 · Cited by 154
Landscape and function of multiple mutations within individual oncogenes
Saito, Y., Koya, J., Araki, M., Kogure, Y., Shingaki, S., Tabata, M., McClure, M. B., Yoshifuji, K., Matsumoto, S., Isaka, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2175-2 · Cited by 146
A modular master regulator landscape controls cancer transcriptional identity
Paull, E. O., Aytes, A., Jones, S. J., Subramaniam, P. S., Giorgi, F. M., Douglass, E. F., Tagore, S., Chu, B., Vasciaveo, A., Zheng, S., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.045 · Cited by 135
Non-coding driver mutations in human cancer
Elliott, K., & Larsson, E. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00371-z · Cited by 166
Prognostic and predictive markers for the new immunotherapies.
Mahoney, K. M., & Atkins, M. B. (2014) · PubMed · Cited by 159
Su, S., Lin, C., Liu, Y., Fan, W., Chen, M., Yu, C.-P., Yang, W., Su, C., Chuang, C., Li, W., et al. (2017) · Theranostics · doi:10.7150/thno.18551 · Cited by 147
Bioinformatics in translational drug discovery
Wooller, S. K., Benstead-Hume, G., Chen, X., Ali, Y., & Pearl, F. M. G. (2017) · Bioscience Reports · doi:10.1042/bsr20160180 · Cited by 147
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations
Huang, F. W., Mosquera, J. M., Garofalo, A., Oh, C., Baco, M. B., Amin‐Mansour, A., Rabasha, B., Bahl, S., Mullane, S. A., Robinson, B. D., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0960 · Cited by 142
Self-citationGenomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Ock, C.-Y., Hwang, J.-E., Keam, B., Kim, S.-B., Shim, J.-J., Jang, H.-J., Park, S., Sohn, B. H., Cha, M., Ajani, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01018-0 · Cited by 138
Mayakonda, A., & Koeffler, H. P. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/052662 · Cited by 138
Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies
Lee, J.-K., Choi, Y.-L., Kwon, M., & Park, P. J. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044446 · Cited by 135
Dufva, O., Kankainen, M., Kelkka, T., Sekiguchi, N., Awad, S. A., Eldfors, S., Yadav, B., Kuusanmäki, H. A., Malani, D., Andersson, E. I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03987-2 · Cited by 144
Spontaneous mutations in the single TTN gene represent high tumor mutation burden
Oh, J., Jang, S. J., Kim, J., Sohn, I., Lee, J., Cho, E. J., Chun, S., & Sung, C. O. (2020) · npj Genomic Medicine · doi:10.1038/s41525-019-0107-6 · Cited by 160
Self-citationCescon, D. W., Haibe-Kains, B., & Mak, T. W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424869112 · Cited by 134
Martelotto, L. G., Ng, C., De Filippo, M. R., Zhang, Y., Piscuoglio, S., Lim, R., Shen, R., Norton, L., Reis-Filho, J. S., & Weigelt, B. (2014) · Genome Biology · doi:10.1186/preaccept-6413622551325626 · Cited by 140
Mao, P., Brown, A. J., Esaki, S., Lockwood, S., Poon, G. M. K., Smerdon, M. J., Roberts, S. A., & Wyrick, J. J. (2018) · Nature Communications · doi:10.1038/s41467-018-05064-0 · Cited by 131
Self-citationNussinov, R., Jang, H., Tsai, C.-J., & Cheng, F. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006658 · Cited by 130
CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers
Tokheim, C., & Karchin, R. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.005 · Cited by 124
Genome instability in multiple myeloma
Neuse, C. J., Lomas, O., Schliemann, C., Shen, Y. J., Manier, S., Bustoros, M. W., & Ghobrial, I. M. (2020) · Leukemia · doi:10.1038/s41375-020-0921-y · Cited by 151
The mini-driver model of polygenic cancer evolution
Castro-Giner, F., Ratcliffe, P. J., & Tomlinson, I. P. M. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3999 · Cited by 149
do Valle, Í. F., Giampieri, E., Simonetti, G., Padella, A., Manfrini, M., Ferrari, A., Papayannidis, C., Zironi, I., Garonzi, M., Bernardi, S., et al. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1190-7 · Cited by 145
Sternberg, C. N., Loriot, Y., James, N. D., Choy, E., Castellano, D., López‐Ríos, F., Banna, G. L., Giorgi, U. D., Masini, C., Bamias, A., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.03.015 · Cited by 140
Sun, Y., Wu, P., Zhang, Z., Wang, Z., Zhou, K., Song, M., Ji, Y., Zang, F., Lou, L., Rao, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.11.010 · Cited by 140
Self-citationReduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair
Polak, P., Lawrence, M. S., Haugen, E., Stoletzki, N., Stojanov, P., Thurman, R. E., Garraway, L. A., Mirkin, S., Getz, G., Stamatoyannopoulos, J. A., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2778 · Cited by 124
Self-citationNesta, A. V., Tafur, D., & Beck, C. R. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.10.003 · Cited by 141
Thind, A. S., Monga, I., Thakur, P. K., Kumari, P., Dindhoria, K., Krzak, M., Ranson, M., & Ashford, B. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab259 · Cited by 129
Tang, H., Sebti, S., Titone, R., Zhou, Y., Isidoro, C., Ross, T. S., Hibshoosh, H., Xiao, G., Packer, M., Xie, Y., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.01.008 · Cited by 128
Tumor microenvironment (TME)-driven immune suppression in B cell malignancy
Nicholas, N. S., Apollonio, B., & Ramsay, A. G. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.003 · Cited by 143
The PKC/NF-κB Signaling Pathway Induces APOBEC3B Expression in Multiple Human Cancers
Leonard, B. C., McCann, J. L., Starrett, G. J., Kosyakovsky, L. B., Luengas, E. M., Molan, A. M., Burns, M. B., McDougle, R. M., Parker, P. J., Brown, W. L., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2171-t · Cited by 145
Immunotherapy for the Treatment of Urothelial Carcinoma
Donin, N. M., Lenis, A. T., Holden, S., Drakaki, A., Pantuck, A. J., Belldegrun, A. S., & Chamie, K. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.02.3005 · Cited by 143
Clinical utility of custom-designed NGS panel testing in pediatric tumors
Surrey, L. F., MacFarland, S. P., Chang, F., Cao, K., Rathi, K. S., Akgumus, G. T., Gallo, D., Lin, F., Gleason, A., Raman, P., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0644-8 · Cited by 133
Age-related somatic mutations in the cancer genome
Milholland, B., Auton, A., Suh, Y., & Vijg, J. (2015) · Oncotarget · doi:10.18632/oncotarget.5685 · Cited by 126
Murakami, R., Matsumura, N., Brown, J. B., Higasa, K., Tsutsumi, T., Kamada, M., Abou-Taleb, H., Hosoe, Y., Kitamura, S., Yamaguchi, K. D., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.06.012 · Cited by 150
Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma
Ren, W., Ye, X., Su, H. L., Li, W., Liu, D., Pirmoradian, M., Wang, X., Zhang, B., Zhang, Q., Chen, L., et al. (2018) · Blood · doi:10.1182/blood-2017-11-817601 · Cited by 130
Cho, R. J., Alexandrov, L. B., den Breems, N. Y., Atanasova, V. S., Farshchian, M., Purdom, E. A., Nguyen, T., Coarfa, C., Rajapakshe, K., di Prisco, M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aas9668 · Cited by 139
Wang, P., Chen, Y., & Wang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672677 · Cited by 156
Abbas, H. A., Hao, D., Tomczak, K. J., Barrodia, P., Im, J. S., Reville, P. K., Alaniz, Z., Wang, W., Wang, R., Wang, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26282-z · Cited by 134
Onco-proteogenomics: cancer proteomics joins forces with genomics
Alfaro, J. A., Sinha, A., Kislinger, T., & Boutros, P. C. (2014) · Nature Methods · doi:10.1038/nmeth.3138 · Cited by 147
Insertions and Deletions Target Lineage-Defining Genes in Human Cancers
Imielinski, M., Guo, G., & Meyerson, M. (2017) · Cell · doi:10.1016/j.cell.2016.12.025 · Cited by 129
“…applied Gamma-Poisson regression (Hilbe, 2014) to statistically account for the regional genomic heterogeneity in neutral somatic variant densities (Lawrence et al., 2013; Polak et al., 2015; Schuster-Böckler and Lehner, 2012) by modeling counts of patients harboring indel or SNV in each interval…”
Self-citationImmunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
Bertucci, F., & Gonçalvès, A. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0627-0 · Cited by 138
The value of cell‐free DNA for molecular pathology
Stewart, C. M., Kothari, P. D., Mouliere, F., Mair, R., Somnay, S., Benayed, R., Zehir, A., Weigelt, B., Dawson, S., Arcila, M. E., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5048 · Cited by 125
Self-citationEhx, G., Larouche, J.-D., Durette, C., Laverdure, J.-P., Hesnard, L., Vincent, K., Hardy, M.-P., Thériault, C., Rulleau, C., Lanoix, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.001 · Cited by 122
Intratumoral heterogeneity and drug resistance in cancer
Fu, Y.-C., Liang, S.-B., Luo, M., & Wang, X. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03734-w · Cited by 148
“Nonetheless, even tumors originating from the same tissue and cell type can exhibit considerable differences in genomic aberrations, invasiveness, and drug sensitivity [37–39].”
KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
Rabara, D., Tran, T. H., Dharmaiah, S., Stephens, R. M., McCormick, F., Simanshu, D. K., & Holderfield, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908353116 · Cited by 128
De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry
Balluff, B., Frese, C. K., Maier, S. K., Schöne, C., Küster, B., Schmitt, M., Aubele, M. M., Höfler, H., Deelder, A. M., Heck, A. J. R., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4436 · Cited by 128
Govindan, R., Mandrekar, S. J., Gerber, D. E., Oxnard, G. R., Dahlberg, S. E., Chaft, J. E., Malik, S. M., Mooney, M., Abrams, J. S., Janne, P. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0354 · Cited by 130
Lv, S., Ji, L., Chen, B., Liu, S., Lei, C., Liu, X., Qi, X., Wang, Y., Leung, E. L., Wang, H., et al. (2017) · Oncogene · doi:10.1038/s41388-017-0026-x · Cited by 135
Pedersen, M., Westergaard, M. C. W., Milne, K., Nielsen, M., Borch, T. H., Poulsen, L. G., Hendel, H. W., Kennedy, M., Briggs, G., Ledoux, S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1502905 · Cited by 135
Effect Sizes of Somatic Mutations in Cancer
Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy168 · Cited by 135
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
Krasniqi, E., Barchiesi, G., Pizzuti, L., Mazzotta, M., Venuti, A., Maugeri‐Saccà, M., Sanguineti, G., Massimiani, G., Sergi, D., Carpano, S., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0798-2 · Cited by 143
Bashraheel, S. S., Dömling, A. S. S., & Goda, S. K. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110009 · Cited by 140
Mutational spectrum of adult T-ALL
Neumann, M., Vosberg, S., Schlee, C., Heesch, S., Schwartz, S., Gökbuget, N., Hoelzer, D. F., Graf, A., Krebs, S., Bartram, I., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2218 · Cited by 135
Variation Interpretation Predictors: Principles, Types, Performance, and Choice
Niroula, A., & Vihinen, M. (2016) · Human Mutation · doi:10.1002/humu.22987 · Cited by 125
“Large numbers of false positives could be identified due to high mutation rates in many cancers and many false negatives due to tumor heterogeneity [Lawrence et al., 2013].”
BackgroundNew agents on the horizon in gastric cancer
Lordick, F., Shitara, K., & Janjigian, Y. Y. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx051 · Cited by 131
A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces
Porta-Pardo, E., Garcia-Alonso, L., Hrabe, T., Dopazo, J., & Godzik, A. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004518 · Cited by 133
Taïeb, D., Jha, A., Treglia, G., & Pacák, K. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0165 · Cited by 137
The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types
Fancello, L., Kampen, K. R., Hofman, I. J. F., Verbeeck, J., & Keersmaecker, K. D. (2017) · Oncotarget · doi:10.18632/oncotarget.14895 · Cited by 122
The evolving genomic landscape of urothelial carcinoma
Glaser, A. P., Fantini, D., Shilatifard, A., Schaeffer, E. M., & Meeks, J. J. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.11 · Cited by 134
Mathematical and Computational Modeling in Complex Biological Systems
Ji, Z., Yan, K., Li, W., Hu, H., & Zhu, X. (2017) · BioMed Research International · doi:10.1155/2017/5958321 · Cited by 145
Analysis of somatic microsatellite indels identifies driver events in human tumors
Maruvka, Y. E., Mouw, K. W., Karlic, R., Parasuraman, P., Kamburov, A., Polak, P., Haradhvala, N. J., Hess, J. M., Rheinbay, E., Brody, Y., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3966 · Cited by 128
Self-citationZhang, X., Choi, P. S., Francis, J. M., Gao, G. F., Campbell, J. D., Ramachandran, A., Mitsuishi, Y., Ha, G., Shih, J., Vazquez, F., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0532 · Cited by 126
Self-citationA global transcriptional network connecting noncoding mutations to changes in tumor gene expression
Zhang, W., Bojorquez-Gomez, A., Velez, D. O., Xu, G., Sanchez, K. S., Shen, J. P., Chen, K., Licon, K., Melton, C., Olson, K. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0091-2 · Cited by 127
Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens
Pan, R., Chung, W., Chu, M.-T., Chen, S.-J., Chen, H.-C., Zheng, L., & Chung, W. (2018) · Journal of Immunology Research · doi:10.1155/2018/4325874 · Cited by 132
Immunotherapy in Ovarian Cancer: Are We There Yet?
Kandalaft, L. E., Odunsi, K. O., & Coukos, G. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00508 · Cited by 136
Integrated mutational landscape analysis of uterine leiomyosarcomas
Choi, J., Manzano, A., Dong, W., Bellone, S., Bonazzoli, E., Zammataro, L. A., Yao, X., Deshpande, A. S., Zaidi, S., Guglielmi, A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025182118 · Cited by 134
Self-citationNeuroendocrine Neoplasms of the Small Bowel and Pancreas
Clift, A. K., Kidd, M. S., Bodei, L., Toumpanakis, C., Baum, R. P., Öberg, K., Modlin, I. M., & Frilling, A. (2019) · Neuroendocrinology · doi:10.1159/000503721 · Cited by 137
In silico saturation mutagenesis of cancer genes
Muiños, F., Martínez-Jiménez, F., Pich, O., Gonzalez-Perez, A., & Lopez-Bigas, N. (2021) · Nature · doi:10.1038/s41586-021-03771-1 · Cited by 126
Shepherd, F. A., Lacas, B., Le Teuff, G., Hainaut, P., Jänne, P. A., Pignon, J.-P., Le Chevalier, T., Seymour, L., Douillard, J.-Y., Graziano, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2893 · Cited by 124
Pemov, A., Li, H., Patidar, R., Hansen, N. F., Sindiri, S., Hartley, S. W., Wei, J. S., ELKAHLOUN, A. G., Chandrasekharappa, S. C., Program, N. C. S., et al. (2017) · Oncogene · doi:10.1038/onc.2016.464 · Cited by 134
Lee, J., Kim, H., Lee, J. E., Shin, S., Oh, S., Kwon, G., Kim, H., Choi, Y. H., White, M. A., Paik, S., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.05.024 · Cited by 133
Mottok, A., Hung, S. S., Chavez, E. A., Woolcock, B. W., Telenius, A., Chong, L. C., Meissner, B., Nakamura, H., Rushton, C. K., Viganò, E., et al. (2019) · Blood · doi:10.1182/blood.2019001126 · Cited by 138
Pan-cancer proteogenomics connects oncogenic drivers to functional states
Li, Y., Porta‐Pardo, E., Tokheim, C. J., Bailey, M. H., Yaron, T. M., Stathias, V., Geffen, Y., Imbach, K. J., Cao, S., Anand, S. K., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.014 · Cited by 136
“On applying these criteria to the large cohorts of cancer genomics data, the list of cancer genes and their predicted driver mutations has grown in recent years.(1,2,11) How these mutations mechanistically ‘‘drive’’ tumorigenesis remains incompletely understood.”
Self-citationGeels, S. N., Moshensky, A., Sousa, R. S., Murat, C., Bustos, M. A., Walker, B. L., Singh, R., Harbour, S. N., Gutierrez, G., Hwang, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.013 · Cited by 141
Pich, O., Muiños, F., Sabarinathan, R., Reyes-Salazar, I., Gonzalez-Perez, A., & Lopez-Bigas, N. (2018) · Cell · doi:10.1016/j.cell.2018.10.004 · Cited by 123
“, 2009), chromatin compaction (Schuster-Böckler and Lehner, 2012), expression level (Lawrence et al., 2013), the binding of transcription factors, the presence of nucleosomes, CTCF binding, and histone marks that distinguish exons from introns, among others (Chen et al.”
Kovac, M., Navas, C., Horswell, S., Salm, M., Bardella, C., Rowan, A., Stares, M., Castro-Giner, F., Fisher, R., de Bruin, E. C., et al. (2015) · Nature Communications · doi:10.1038/ncomms7336 · Cited by 121
Meyer, M. J., Lapcevic, R., Romero, A. E., Yoon, M., Das, J., Beltrán, J. F., Mort, M., Stenson, P. D., Cooper, D. N., Paccanaro, A., et al. (2016) · Human Mutation · doi:10.1002/humu.22963 · Cited by 125
“…the wholesale sequencing of tumor samples, and an accompanying class of statistical methods to identify genes characterized by elevated mutation rates across large patient cohorts [Sjöblom et al., 2006; Wood et al., 2007; Cancer Genome Atlas, 2012; Hodis et al., 2012; Lawrence et al., 2013, 2014].”
MethodInfluentialIntegrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types
Ge, Z., Leighton, J. S., Wang, Y., Peng, X., Chen, Z., Chen, H., Sun, Y., Yao, F., Li, J., Zhang, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.047 · Cited by 125
Self-citationPitt, J. J., Riester, M., Zheng, Y., Yoshimatsu, T. F., Sanni, A., Oluwasola, O., Veloso, A., Labrot, E., Wang, S., Odetunde, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06616-0 · Cited by 161
Self-citationShah, N. J., Najibi, A. J., Shih, T., Mao, A. S., Sharda, A., Scadden, D. T., & Mooney, D. J. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0503-3 · Cited by 123
Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure
Tokheim, C., Bhattacharya, R., Niknafs, N., Gygax, D. M., Kim, R., Ryan, M., Masica, D. L., & Karchin, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3190 · Cited by 132
“sequenced in order to attain 90% power to detect mutations in 90% of genes with a mutation frequency of 2% with the SMG approach (5).”
BackgroundLi, X., Wu, W. K. K., Xing, R., Wong, S. H., Liu, Y., Fang, X., Zhang, Y., Wang, M., Wang, J., Li, L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2443 · Cited by 132
Oesophageal adenocarcinoma and gastric cancer: should we mind the gap?
Hayakawa, Y., Sethi, N. S., Sepulveda, A. R., Bass, A. J., & Wang, T. C. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.24 · Cited by 134
Self-citationInsights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
Nguyen, B., Mota, J. M., Nandakumar, S., Stopsack, K. H., Weg, E. S., Rathkopf, D. E., Morris, M. J., Scher, H. I., Kantoff, P. W., Gopalan, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.03.024 · Cited by 135
Saunus, J. M., Quinn, M. C. J., Patch, A., Pearson, J. V., Bailey, P. J., Nones, K., Reed, A. E. M., Miller, D. K., Wilson, P. J., Al‐Ejeh, F., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4583 · Cited by 130
Pan-Cancer Analysis of Mutation Hotspots in Protein Domains
Miller, M. L., Reznik, E., Gauthier, N. P., Aksoy, B. A., Korkut, A., Gao, J., Ciriello, G., Schultz, N., & Sander, C. (2015) · Cell Systems · doi:10.1016/j.cels.2015.08.014 · Cited by 118
“S̄ = − ∑n i=1 P (xi) lnP (xi) lnn (5) where n is the dimension of the vector x.”
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., Kiezun, A., Hammerman, P. S., McKenna, A., Drier, Y., Zou, L., Ramos, A. H., Pugh, T. J., Stransky, N., Helman, E., Kim, J., Sougnez, C., Ambrogio, L., Nickerson, E., Shefler, E., Cortés, M. L., Auclair, D., Saksena, G., Voet, D., Noble, M., DiCara, D., Lin, P., Lichtenstein, L., Heiman, D. I., Fennell, T., Imielinski, M., Hernandez, B., Hodis, E., Baca, S., Dulak, A. M., Lohr, J., Landau, D.-A., Wu, C. J., Melendez-Zajgla, J., Hidalgo-Miranda, A., Koren, A., McCarroll, S. A., Mora, J., Lee, R. S., Crompton, B., Onofrio, R., Parkin, M., Winckler, W., Ardlie, K., Gabriel, S. B., Roberts, C. W. M., Biegel, J. A., Stegmaier, K., Bass, A. J., Garraway, L. A., Meyerson, M., Golub, T. R., Gordenin, D. A., Sunyaev, S., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- National Institutes of Health (US)
- Harvard University (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Boston Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Lawrence, Michael S.
- Polak, Paz
- Kryukov, Gregory V.
- Cibulskis, Kristian
- Sivachenko, Andrey
- Carter, Scott L.
- Stewart, Chip
- Mermel, Craig H.
- Roberts, Steven A.
- Hammerman, Peter S.
- McKenna, Aaron
- Drier, Yotam
- Zou, Lihua
- Pugh, Trevor J.
- Stransky, Nicolas
- Helman, Elena
- Kim, Jaegil
- Auclair, Daniel
- Saksena, Gordon
- Noble, Michael
- Lin, Pei
- Heiman, David I.
- Imielinski, Marcin
- Hernandez, Bryan
- Hodis, Eran
- Baca, Sylvan
- Dulak, Austin M.
- Lohr, Jens
- Landau, Dan-Avi
- Wu, Catherine J.
- Koren, Amnon
- McCarroll, Steven A.
- Mora, Jaume
- Crompton, Brian
- Winckler, Wendy
- Ardlie, Kristin
- Gabriel, Stacey B.
- Roberts, Charles W. M.
- Biegel, Jaclyn A.
- Stegmaier, Kimberly
- Bass, Adam J.
- Garraway, Levi A.
- Meyerson, Matthew
- Golub, Todd R.
- Gordenin, Dmitry A.
- Sunyaev, Shamil
- Lander, Eric S.
- Getz, Gad
- Venue
- Nature
- Published
- 2013-06-16
- Volume
- 499
- Issue
- 7457
- Pages
- 214-218
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3919509
- OpenAlex
- W2009720434
- Cited by
- 5,461
- References
- 30
- Citations by year
- 2026: 147 · 2025: 230 · 2024: 288 · 2023: 361 · 2022: 468 · 2021: 580 · 2020: 582 · 2019: 507 · 2018: 537 · 2017: 529 · 2016: 485 · 2015: 396 · 2014: 280 · 2013: 64
- FWCI
- 143.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U24CA143845, T32CA009216, T32CA009172)
- National Institute of General Medical Sciences (T32GM007753)
- National Institute of Environmental Health Sciences (Z01ES065073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
- Keywords
- mutational heterogeneity, cancer genes, MutSigCV, driver mutations, mutation frequency, lung cancer, lung squamous cell carcinoma, DNA replication timing, transcriptional activity
- MeSH terms
- False Positive Reactions, Humans, Lung Neoplasms, Mutation, Neoplasms, Oncogenes, Reproducibility of Results, Gene Expression, Genome, Human, Artifacts, Neoplasms, Squamous Cell, Sample Size, Genetic Heterogeneity, DNA Replication Timing, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.